Fig. 2

PD-L1 expression is induced by IL-6 via the JAK1/Stat3 signaling pathway. A–C RNA analysis of the correlation between IL-6 and PD-L1 expression in tumor tissues of patients with NSCLC (A), patients with LUAD (B), and patients with LUSC (C) in the TCGA dataset. D–F IHC analysis of the correlation between IL-6 and PD-L1 expression in tumor tissues of patients with NSCLC (D), patients with LUAD (E), and patients with LUSC (F) at the CICAMS. G Western blotting analysis of PD-L1, Stat3 and p-Stat3 expression in control or IL-6-overexpressimg A549 and H1703 cells with or without cotreatment of ruxolitinib (10umol/L) for 24 h. H Western blotting analysis of PD-L1, Stat3 and p-Stat3 expression in A549 and H1703 cells with or without exposure to IL-6 (20 ng/mL) and ruxolitinib (10umol/L) for 24 h. I Tumoricidal activity of CD8⁺ T cells cocultured with control or IL-6-overexpressing A549 and H1703 cells after treatment with isotype control and durvalumab (1500 μg/mL) for 48 h. J Tumoricidal activity of CD8⁺ T cells cocultured with A549 and H1703 cells in the presence or absence of IL-6 (20 ng/mL) after treatment with isotype control and durvalumab (1,500 μg/mL) for 48 h. VEC, control group; OE, overexpressing group